Office of National Drug Control Policy Reauthorization Act of 2024

This bill reauthorizes the Office of National Drug Control Policy through 2031 with updated definitions and expanded focus on harm reduction. Key provisions include requiring the Director to submit a report on opioid overdose reversal medications like naloxone, increasing funding for fentanyl interdiction activities ($5 million minimum annually), and expanding data collection requirements on drug use patterns and treatment effectiveness. The bill updates definitions to better address emerging drug threats and precursor chemicals, and mandates a Caribbean Border Counternarcotics Strategy to address drug trafficking through the Caribbean region. It affects federal agencies involved in drug control, law enforcement, and public health, requiring coordinated efforts to reduce drug use and improve access to life-saving treatments.